PlainRecalls
FDA Drug Moderate Class II Terminated

Glimepiride Tablets, USP, 2 mg, RX, Packaged as a ) 100-count bottle, NDC# 68001-178-00; b) 500-count bottle; NDC# 68001-178-03 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. For BluePoint Laboratories

Reported: May 31, 2023 Initiated: March 17, 2023 #D-0758-2023

Product Description

Glimepiride Tablets, USP, 2 mg, RX, Packaged as a ) 100-count bottle, NDC# 68001-178-00; b) 500-count bottle; NDC# 68001-178-03 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. For BluePoint Laboratories

Reason for Recall

CGMP Deviations: recalling drug products following an FDA inspection.

Details

Units Affected
105,361 bottles
Distribution
Nationwide USA
Location
Columbus, OH

Frequently Asked Questions

What product was recalled?
Glimepiride Tablets, USP, 2 mg, RX, Packaged as a ) 100-count bottle, NDC# 68001-178-00; b) 500-count bottle; NDC# 68001-178-03 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. For BluePoint Laboratories. Recalled by Amerisource Health Services LLC. Units affected: 105,361 bottles.
Why was this product recalled?
CGMP Deviations: recalling drug products following an FDA inspection.
Which agency issued this recall?
This recall was issued by the FDA Drug on May 31, 2023. Severity: Moderate. Recall number: D-0758-2023.